
The first day of CRDSA’s 2025 Summit explored the current state of patient data reuse in the regulatory approval process. Presentations and the expert panel discussed why responsible data reuse is a critical tool in future trial design, how the totality of evidence can inform the drug development process, and what’s needed to meet regulatory use challenges.
- C-Path’s use of patient-level data in the regulatory pathway (Keynote)
- The Intersection of Data Sharing and Equitable Healthcare: Challenges and Opportunities (Presentation)
- Innovative Trial Design: Data Reuse Opportunities and Regulatory Considerations (Panel)


